Welcome to our dedicated page for Calidi Biotherapeutics news (Ticker: CLDI), a resource for investors and traders seeking the latest updates and insights on Calidi Biotherapeutics stock.
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) is a clinical-stage immuno-oncology company developing systemically delivered, targeted genetic medicines based on its proprietary RedTail platform. This news page aggregates company-issued updates and related coverage so readers can follow how Calidi advances its oncolytic virus-based therapies and corporate strategy over time.
Calidi’s announcements frequently highlight progress with CLD-401, the first lead candidate from the RedTail platform. News items include preclinical data presented at scientific meetings such as the Society for Immunotherapy of Cancer (SITC) Annual Meeting, where the company has reported that its engineered enveloped oncolytic virus can avoid immune clearance after systemic administration, home to metastatic tumor sites, and express IL-15 superagonist and other genetic medicines within the tumor microenvironment.
Investors can also find updates on Calidi’s broader activities, including the formation of a Scientific Advisory Board, participation in investor conferences, and capital markets events such as underwritten public offerings. Press releases describe how the company is working with partners, such as a viral vector CDMO, to provide analytical development, process development, and GMP manufacturing support for CLD-401 as it moves through IND-enabling studies.
By reviewing the CLDI news feed, readers can track scientific milestones, financing developments, strategic collaborations, and investor communications related to Calidi’s efforts to develop RedTail-based virotherapies and protected intratumoral programs. This page is a useful reference for following the company’s disclosed progress in immuno-oncology and genetic medicine research.
Summary not available.
Summary not available.
Summary not available.